Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and Hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin

Infection and Immunity

Volumn 68, Issue 12, 2000, Pages 7094-7099

  Chambers, Mark A ^a   Williams, Ann ^b   Gavier Widén, Dolores ^a,d   Whelan, Adam ^a   Hall, Graham ^b   Marsh, Philip D ^b   Bloom, Barry R ^c   Jacobs, William R ^c   Hewinson, R Glyn ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; LEUCINE; TUBERCULIN;

ANIMAL TISSUE; ARTICLE; AUXOTROPHIC MUTANT; BACTERIUM IDENTIFICATION; BACTERIUM MUTANT; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; GUINEA PIG; IMMUNITY; LUNG; LUNG TUBERCULOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUBERCULIN TEST; TUBERCULOSIS;

ANIMALS; BCG VACCINE; CATTLE; GUINEA PIGS; HYPERSENSITIVITY, DELAYED; LEUCINE; MUTAGENESIS, INSERTIONAL; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 0034442696     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.12.7094-7099.2000     Document Type: Article

References (37)

1. Baldwin, S. L., C. D'Souza, A. D. Roberts, B. P. Kelly, A. A. Frank, M. A. Lui, J. B. Ulmer, K. Huygen, D. M. McMurray, and I. M. Orme. 1998. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66:2951-2959.
2. Bloom, B. R., and P. E. M. Fine. 1994. The BCG experience: implications for future vaccines against tuberculosis, p. 531-557. In B. R. Bloom (ed.), Tuberculosis: pathogenicity, protection, and control. American Society for Microbiology, Washington, D.C.
3. Brandely, M., B. Hurtrel, and P. H. Lagrange. 1983. Comparison between immunopotency tests and specific active or passive acquired resistance against Mycobacterium tuberculosis in mice induced with three different preparations of BCG pasteur vaccine. Clin. Exp. Immunol. 54:143-150.
4. Crubezy, E., B. Ludes, J. D. Poveda, J. Clayton, B. Crouau-Roy, and D. Montagnon. 1998. Identification of Mycobacterium DNA in an Egyptian Pott's disease of 5,400 years old. C. R. Acad. Sci. III 321:941-951.
5. Dankner, W. M., N. J. Waecker, M. A. Essey, K. Moser, M. Thompson, and C. E. Davis. 1993. Mycobacterium bovis infections in San Diego: a clinico-epidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine (Baltimore) 72:11-37.
6. Druett, H. A. 1969. A mobile form of the Henderson apparatus. J. Hyg. 67:437-448.
7. European Pharmacopoeia. 1997. European pharmacopoeia, 3rd ed., p. 1680-1681. European Pharmacopoeia, Strasbourg, France.
8. Fine, P. E., J. A. Sterne, J. M. Ponnighaus, and R. J. Rees. 1994. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 344:1245-1249.
9. Grange, J. M., and C. H. Collins. 1987. Bovine tubercle bacilli and disease in animals and man. Epidemiol. Infect. 99:221-234.
10. Guleria, I., R. Teitelbaum, R. A. McAdam, G. Kalpana, W. R. Jacobs, Jr., and B. R. Bloom. 1996. Auxotrophic vaccines for tuberculosis. Nat. Med. 2:334-337.
11. Hart, P. D., I. Sutherland, and J. Thomas. 1967. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in induced tuberculin sensitivity and to technical variations in the vaccines. Tubercle 48:201-210.
12. Hart, P. D., and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 2:293-295.
13. Hattori, H., F. Yamaguchi, N. Wagai, M. Kato, and M. Nomura. 1997. An assessment of antigenic potential of beta-lactam antibiotics, low molecular weight drugs, using guinea pig models. Toxicology 123:149-160.
14. Hewinson, R. G., S. L. Michell, W. P. Russell, R. A. McAdam, and W. J. Jacobs. 1996. Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand. J. Immunol. 43:490-499.
15. Hondalus, M. K., S. Bardarov, R. Russell, J. Chan, W. R. Jacobs, Jr., and B. R. Bloom. 2000. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. 68:2888-2898.
16. Ishibashi, T., Y. Harada, S. Harada, H. Yamada, M. Takamoto, and K. Sugiyama. 1978. Mode of immunopotentiating action of BCG: persistence and spread of BCG infection. Jpn. J. Exp. Med. 48:227-232.
17. Jackson, M., S. W. Phalen, M. Lagranderie, D. Ensergueix, P. Chavarot, G. Marchal, D. N. McMurray, B. Gicquel, and C. Guilhot. 1999. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 67:2867-2873.
18. Jacobs, W. R., Jr., G. V. Kalpana, J. D. Cirillo, L. Pascopella, S. B. Snapper, R. A. Udani, W. Jones, R. G. Barletta, and B. R. Bloom. 1991. Genetic systems for mycobacteria. Methods Enzymol. 204:537-555.
19. Jirova, D., V. Janeckova, S. Znojemska, and J. Pekarek. 1983. Adjuvant activity of muramyldipeptide in a guinea pig model of contact allergy to chromium. J. Hyg. Epidemiol. Microbiol. Immunol. 27:395-402.
20. Johnson, C. M., A. M. Cooper, A. A. Frank, and I. M. Orme. 1998. Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis - infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect. Immun. 66:1665-1670.
21. Jungblut, P. R., U. E. Schaible, H. Mollenkopf, U. Zimny-Arndt, B. Raupach, J. Mattow, P. Halada, S. Lamer, K. Hagens, and S. H. Kaufmann. 1999. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol. Microbiol. 33:1103-1117.
22. Krebs, J., R. Anderson, T. Clutton-Brock, I. Morrison, D. Young, and C. Donnelly. 1997. Bovine tuberculosis in cattle and badgers - report by the Independent Scientific Review Group. Ministry of Agriculture, Fisheries and Food Publications, London, United Kingdom.
23. Lobato, M. N., and P. C. Hopewell. 1998. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am. J. Respir. Crit. Care Med. 158:1871-1875.
24. McAdam, R. A., T. R. Weisbrod, J. Martin, J. D. Scuderi, A. M. Brown, J. D. Cirillo, B. R. Bloom, and W. R. Jacobs, Jr. 1995. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect. Immun. 63:1004-1012.
25. McMurray, D. N. 1994. Guinea pig model of tuberculosis, p. 135-147. In B. R. Bloom (ed.), Tuberculosis: pathogenicity, protection, and control. American Society for Microbiology, Washington, D.C.
26. O'Reilly, L. M., and C. J. Daborn. 1995. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuber. Lung Dis. 76(Suppl. 1):1-46.
27. Orme, I. M. 1988. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect. Immun. 56:3310-3312.
28. Salo, W. L., A. C. Aufderheide, J. Buikstra, and T. A. Holcomb. 1994. Identification of Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. Proc. Natl. Acad. Sci. USA 91:2091-2094.
29. Steele, J. H. 1995. Regional and country status reports - introduction, p. 47-61. In C. O. Thoen and J. H. Steele (ed.), Mycobacterium bovis infection in animals and humans. Iowa State University Press, Ames.
30. Tuberculosis Prevention Trial, Madras. 1980. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J. Med. Res. 72(Suppl. 1): 1-74.
31. Vial, T., and J. Descotes. 1994. Contact sensitization assays in guinea-pigs: are they predictive of the potential for systemic allergic reactions? Toxicology 93:63-75.
32. Vordermeier, H. M., P. C. Cockle, A. Whelan, S. Rhodes, N. Palmer, D. Bakker, and R. G. Hewinson. 1999. Development of diagnostic reagents to differentiate between Mycobacterium bovis BCG vaccination and M. bovis infection in cattle. Clin. Diagn. Lab. Immunol. 6:675-682.
33. Wedlock, D. N., F. E. Aldwell, D. M. Collins, G. W. de Lisle, T. Wilson, and B. M. Buddle. 1999. Immune responses induced in cattle by virulent and attenuated Mycobacterium bovis strains: correlation of delayed-type hypersensitivity with ability of strains to grow in macrophages. Infect. Immun. 67:2172-2177.
34. Williams, A., A. Davies, P. D. Marsh, M. A. Chambers, and R. G. Hewinson. 2000. Comparison of the protective efficacy of bacille Calmette-Guerin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin. Infect. Dis. 30(Suppl. 3):299-301.
35. Williams, D. E. 1995. Mycobacterium bovis BCG infection in humans, p. 47-61. In C. O. Thoen and J. H. Steele (ed.), Mycobacterium bovis infection in animals and humans. Iowa State University Press, Ames.
36. World Health Organization. 1959. Joint WHO/FAO Expert Committee on Zoonoses. Technical report series 169. World Health Organization, Geneva, Switzerland.
37. Youmans, G. P. 1975. Relation between delayed hypersensitivity and immunity in tuberculosis. Am. Rev. Respir. Dis. 111:109-118.